1. Volume 16, Issue 6, Pages 656-666 (June 2015)
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial 
Dr Helena M Earl, MBBS, Louise Hiller, PhD, Prof Janet A Dunn, PhD, Clare Blenkinsop, Louise Grybowicz, BSc, Anne-Laure Vallier, MSc, Jean Abraham, MBBS, Jeremy Thomas, MBBS, Elena Provenzano, MD, Luke Hughes-Davies, MBBCh, Ioannis Gounaris, MD, Karen McAdam, MBBS, Stephen Chan, MBBCh, Rizvana Ahmad, MBBS, Tamas Hickish, MBBS, Stephen Houston, MBBS, Daniel Rea, PhD, Prof John Bartlett, PhD, Prof Carlos Caldas, MD, Prof David A Cameron, MD, Larry Hayward, MBChB 
The Lancet Oncology 
Volume 16, Issue 6, Pages (June 2015)
DOI: /S (15)
Copyright © 2015 Earl et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions

2. Figure 1
Trial profile
D-FEC=docetaxel 100 mg/m2 once every 21 days, followed by fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2 once every 21 days. Bev+D-FEC=bevacizumab 15 mg/kg given every 3 weeks with the first four cycles of chemotherapy (D-FEC).
The Lancet Oncology  , DOI: ( /S (15) )
Copyright © 2015 Earl et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions

3. Figure 2
Effect of bevacizumab on pathological complete response according to oestrogen receptor (ER) status
The Lancet Oncology  , DOI: ( /S (15) )
Copyright © 2015 Earl et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions